Integra LifeSciences Holdings Corporation (IART) Stock Score, Valuation & Financial Research
Integra LifeSciences Holdings Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for IART
Integra LifeSciences Holdings Corporation currently has a Wall Street Score of 23/100. The stored market price is $15.5. Its financial score is 45/100. Its valuation score is 0/100. The latest WSS change is -1.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What Integra LifeSciences Holdings Corporation does
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance
IART financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $15.5
- Market capitalization:
- $1.21B
- Revenue:
- $1.65B
- Net income:
- $-7.2M
- Free cash flow:
- $-45.3M
- Cash:
- $214.4M
- Total debt:
- $2.04B
- EPS:
- -6.73
- Financial score:
- 45/100
- Valuation score:
- 0/100
- Revenue score:
- 15/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-45.3M, showing cash burn in the current stored period.
- The balance sheet shows $214.4M of cash versus $2.04B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -1.5 points: IART decreased 1.5 points because Debt declined by 11.2 points, Buffett declined by 2.7 points.
- The current research record carries a high debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 45/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IART
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.